NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…
Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…
WHO Expects HCQ Safety Findings by Mid-June
ZURICH (Reuters)—The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine (HCQ), probably by mid-June, after safety concerns prompted the group to suspend the malaria drug’s use in a trial on COVID-19 patients. U.S. President Donald Trump and others have pushed HCQ as a possible coronavirus treatment, but the WHO…
Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
(Reuters)—Malaria drug hydroxychloroquine (HCQ), which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in The Lancet.1 The registry analysis, which included data from 671 hospitals in six continents and over 96,000 patients hospitalized with COVID-19, showed that people treated…
U.K. Healthcare Workers Begin COVID-19 HCQ Trial
LONDON (Reuters)—On May 21, British healthcare workers began taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking. The COPCOV study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and…
Rheumatology Education Goes ViRL: New Online Courses Use Interactive Platforms to Engage Fellows
Interactive rheumatology education has flourished online thanks to grassroots efforts & ACR support…
AMA House of Delegates Meeting Postponed Due to COVID-19, Advocacy Efforts Continue
Due to the COVID-19 pandemic, the AMA House of Delegates meeting planned for June has been canceled, but the ACR’s delegation remains ready to advocate for both ongoing and new rheumatology issues, including patient protections in step therapy, prior authorization and expansion of telehealth.
Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease
A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.
Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…
Fellowship Training Goes Virtual: COVID-19 Pandemic Creates Training Challenges
With telemedicine platforms and Zoom calls, technology is playing a large role in how rheumatology fellows are seeing patients and participating in lectures and conferences…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 27
- Next Page »